HarrietMargotKlugerMD

Professor of Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program; Assistant Cancer Center Director for Education and Training Yale School of Medicine

Join to view full profile

Dr. Kluger is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Kluger's full profile

Already have an account?

Office
800 Howard Ave
Yale Physicians Building 2ND floor
New Haven, CT 06519
Phone+1 203-688-4191

Fax+1 203-737-2617

Education & Training

Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 1999 - 2002
Alameda Health System-Highland HospitalResidency, Internal Medicine, 1995 - 1996
University of New Mexico School of MedicineResidency, Internal Medicine, 1993 - 1995
Tel Aviv University SacklerClass of 1992

Certifications & Licensure

CA State Medical License 1995 - Present
CT State Medical License 2000 - 2025
FL State Medical License 2020 - 2022
NM State Medical License 1993 - 2000
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma Start of enrollment: 2006 Dec 01
Completed
Phase 2
Phase I/II Study to Assess the Safety and Activity of Enhanced TCR Transduced Autologous T Cells in Metastatic Melanoma Start of enrollment: 2011 Jun 01
Terminated
Phase 1, Phase 2
Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma. Start of enrollment: 2013 Jul 01
Terminated
Phase 1, Phase 2
Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases Start of enrollment: 2013 Apr 01
Completed
Phase 2
MK-3475 in Melanoma and NSCLC Patients With Brain Metastases Start of enrollment: 2014 Mar 01
Completed
Phase 2
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases Start of enrollment: 2015 Feb 01
Terminated
Phase 2
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer Start of enrollment: 2016 May 01
Recruiting
Phase 2
APX005M With Nivolumab and Cabiralizumab in Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Carcinoma Start of enrollment: 2018 Jun 09
Active, not recruiting
Phase 1
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Start of enrollment: 2020 Sep 14
Active, not recruiting
Phase 1
Roles: Contact, Principal Investigator
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas Start of enrollment: 2018 Oct 24
Terminated
Phase 1
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

343 citations
Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
Rituparna Das, Rakesh Verma, Mario Sznol, Chandra Sekhar Boddupalli, Scott N. Gettinger
Journal of Immunology. 2015-02-01
35 citations
Melanoma central nervous system metastases: current approaches, challenges, and opportunities.
Justine V Cohen, Hussain Tawbi, Kim A Margolin, Ravi Amravadi, Marcus Bosenberg
Pigment Cell & Melanoma Research. 2016-11-01
318 citations
Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients.
Miguel F. Sanmamed, Jose Luis Perez-Gracia, Kurt A. Schalper, J.P. Fusco, Alvaro Gonzalez
Annals of Oncology. 2017-08-01

Journal Articles

Assessment of Age, Period, and Birth Cohort Effects and Trends in Merkel Cell Carcinoma Incidence in the United States
Harriet Kluger, MD, JAMA Dermatology
Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung Carcinoma
Beth A Hellerstedt, Nicholas J Vogelzang, Harriet M Kluger, Christopher A Yasenchak, Michael S Gordon, Primo Lara, Clinical Lung Cancer

Lectures

Updated Efficacy Studies of Anti-PD-1 Therapy and Associated Biomarkers
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
14th Therapeutic ERCP-EUS Workshop
Yale CME, New Haven, Connecticut - 3/23/2012
Yale Cancer Center Evening Oncology Series: Melanoma
Yale CME, New Haven, Connecticut - 3/15/2012

Authored Content

Results of a Phase 2 Placebo-Controlled Randomized Discontinuation Trial of Cabozantinib in Patients with Non–Small-Cell Lung CarcinomaOctober 2018

Press Mentions

Yale Study Highlights Unmet Needs for Patients with Melanoma Who Progress or Relapse After Immunotherapy TreatmentAugust 30th, 2024
Apexigen to Host Key Opinion Leader Webinar on Sotigalimab in Post-Anti-PD-(L)1 MelanomaNovember 9th, 2021
The Society for Immunotherapy of Cancer (SITC) Invites You to Attend the Virtual Press Briefing of the Society’s 36th Anniversary Annual MeetingNovember 2nd, 2021
Join now to see all

Grant Support

Models To Predict Prognosis And Benefit From Adjuvant Therapy In Renal Cell CarciNational Cancer Institute2011–2012
Predicting Melanoma Response To BAY 43-9006/ChemotherapyNational Cancer Institute2005–2008